Correction: Liver Safety of the Dual Neurokinin‑1/‑3 Receptor Antagonist Elinzanetant
Drug Safety · 2026-08 · 49 (8) · 1003-1003
DOI: 10.1007/s40264-026-01675-5 ↗Kurz gefasst
Korrektur in der Zeitschrift Drug Safety, online erschienen am 17.04.2026. Verfasst von James H Lewis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Georgetown University Medical Center, Washington, DC, USA. lewisjh9205@gmail.com. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Georgetown University Medical Center, Washington, DC, USA. lewisjh9205@gmail.com.
- Instituto de Investigación Biomédica de Málaga-IBIMA Plataforma Bionand, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, CIBERehd, Málaga, Spain.
- Liver Unit, Saint-Eloi Hospital, Montpellier School of Medicine, Montpellier, France.
- Department of Hepato-Gastroenterology, Cliniques Universitaires Saint-Luc et Institut de Recherche Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium.
- Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.
- Bayer US LLC, Whippany, NJ, USA.
Zitieren
APA
Lewis, J. H., Andrade, R. J., Larrey, D., Horsmans, Y., Anderson, R. A., Trajanovic, M., Groettrup-Wolfers, E., & Zuurman, L. (2026). Correction: Liver Safety of the Dual Neurokinin‑1/‑3 Receptor Antagonist Elinzanetant. Drug Safety, 49(8), 1003-1003. https://doi.org/10.1007/s40264-026-01675-5
Vancouver
Lewis JH, Andrade RJ, Larrey D, Horsmans Y, Anderson RA, Trajanovic M, et al. Correction: Liver Safety of the Dual Neurokinin‑1/‑3 Receptor Antagonist Elinzanetant. Drug Safety. 2026;49(8):1003-1003. doi:10.1007/s40264-026-01675-5
BibTeX
@article{Lewis2026,
author = {Lewis, James H and Andrade, Raúl J and Larrey, Dominique and Horsmans, Yves and Anderson, Richard A and Trajanovic, Mila and Groettrup-Wolfers, Esther and Zuurman, Lineke},
title = {Correction: Liver Safety of the Dual Neurokinin‑1/‑3 Receptor Antagonist Elinzanetant},
journal = {Drug Safety},
year = {2026},
volume = {49},
number = {8},
pages = {1003--1003},
doi = {10.1007/s40264-026-01675-5}
}
EUVIMED